Peter Powchik - Net Worth and Insider Trading
Peter Powchik Net Worth
The estimated net worth of Peter Powchik is at least $25 Million dollars as of 2024-11-13. Peter Powchik is the SVP Clinical Development & Reg of Regeneron Pharmaceuticals Inc and owns about 30,363 shares of Regeneron Pharmaceuticals Inc (REGN) stock worth over $25 Million. Details can be seen in Peter Powchik's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Peter Powchik has not made any transactions after 2015-08-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Peter Powchik
Peter Powchik Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Peter Powchik owns 2 companies in total, including Regeneron Pharmaceuticals Inc (REGN) , and Vaxxinity Inc (VAXX) .
Click here to see the complete history of Peter Powchik’s form 4 insider trades.
Insider Ownership Summary of Peter Powchik
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | 2015-08-14 | SVP & Clinical Development |
| VAXX | Vaxxinity Inc | 2022-03-31 | director |
Peter Powchik Latest Holdings Summary
Peter Powchik currently owns a total of 1 stock. Peter Powchik owns 30,363 shares of Regeneron Pharmaceuticals Inc (REGN) as of August 14, 2015, with a value of $25 Million.
Latest Holdings of Peter Powchik
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | 2015-08-14 | 30,363 | 821.00 | 24,928,023 |
Holding Weightings of Peter Powchik
Peter Powchik Form 4 Trading Tracker
According to the SEC Form 4 filings, Peter Powchik has made a total of 0 transactions in Regeneron Pharmaceuticals Inc (REGN) over the past 5 years. The most-recent trade in Regeneron Pharmaceuticals Inc is the sale of 23,485 shares on August 14, 2015, which brought Peter Powchik around $13 Million.
Insider Trading History of Peter Powchik
- 1
Peter Powchik Trading Performance
Peter Powchik Ownership Network
Ownership Network List of Peter Powchik
Ownership Network Relation of Peter Powchik
Peter Powchik Owned Company Details
What does Regeneron Pharmaceuticals Inc do?
Who are the key executives at Regeneron Pharmaceuticals Inc?
Peter Powchik is the SVP & Clinical Development of Regeneron Pharmaceuticals Inc. Other key executives at Regeneron Pharmaceuticals Inc include SVP Commercial Marion Mccourt , VP & Controller Christopher R. Fenimore , and EVP Research Andrew J Murphy .
Regeneron Pharmaceuticals Inc (REGN) Insider Trades Summary
Over the past 18 months, Peter Powchik made no insider transaction in Regeneron Pharmaceuticals Inc (REGN). Other recent insider transactions involving Regeneron Pharmaceuticals Inc (REGN) include a net sale of 10,814 shares made by Marion Mccourt , a net sale of 1,400 shares made by Arthur F Ryan , and a net sale of 7,918 shares made by Bonnie L Bassler .
In summary, during the past 3 months, insiders sold 26,837 shares of Regeneron Pharmaceuticals Inc (REGN) in total and bought 0 shares, with a net sale of 26,837 shares. During the past 18 months, 315,919 shares of Regeneron Pharmaceuticals Inc (REGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 315,919 shares.
Regeneron Pharmaceuticals Inc (REGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regeneron Pharmaceuticals Inc Insider Transactions
Peter Powchik Mailing Address
Above is the net worth, insider trading, and ownership report for Peter Powchik. You might contact Peter Powchik via mailing address: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown Ny 10591.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
